Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and produce exceptional returns. But finding a great growth ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

The consensus price target hints at a 36.6% upside potential for BioMarin (BMRN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate ...

Smartleaf Asset Management LLC grew its holdings in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 111.2% in the 4th quarter, according to the company in its most recent 13F ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) is anticipated to release its earnings data before the market opens on Thursday, February 27th. Analysts expect BioMarin Pharmaceutical to post ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

Fintel reports that on February 24, 2025, Oppenheimer upgraded their outlook for BioMarin Pharmaceutical (NasdaqGS:BMRN) from Perform to Outperform. Analyst Price Forecast Suggests 44.46% Upside As of ...

The mother of a six-year-old girl with a rare neurodegenerative disease has urged health bosses to "do the right thing" amid ...

In a report released today, Phil Nadeau from TD Cowen maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with a price ...

Ladies and gentlemen, thank you for standing by and welcome to the BioMarin Pharmaceuticals fourth quarter and full year 2024 conference call. All lines have been placed on mute to prevent any ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...